Werewolf Therapeutics Announces Sale Of Preclinical INDUCER And INDUKINE Platform Assets To EMD Serono For $28M Upfront, Plus $5M On Technology Transfer Completion

Loading news article.

Werewolf Therapeutics Announces Sale Of Preclinical INDUCER And INDUKINE Platform Assets To EMD Serono For $28M Upfront, Plus $5M On Technology Transfer Completion | WAPE

Werewolf Therapeutics Announces Sale Of Preclinical INDUCER And INDUKINE Platform Assets To EMD Serono For $28M Upfront, Plus $5M On Technology Transfer Completion

Article summary

Related companies

Comments —